Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

This phase 3, open label trial compared the efficacy and safety of once weekly tirzepatide (a dual glucose dependent insulinotropic polypeptide and GLP1 receptor agonist) with semaglutide (a selective GLP1 receptor agonist) in patients with type 2 diabetes inadequately controlled by metformin. The study involved 1879 patients randomized to receive tirzepatide (5 mg, 10 mg, or 15 mg) or semaglutide (1 mg) for 40 weeks. Results showed that tirzepatide was superior to semaglutide in reducing glycated hemoglobin levels (2.01 to 2.30 percentage points vs. 1.86 percentage points) and body weight (7.6 to 11.2 kg vs. 5.7 kg). Gastrointestinal adverse events were common but mostly mild to moderate. Tirzepatide demonstrated noninferiority and superiority to semaglutide, offering a promising treatment option for type 2 diabetes.

This phase 3, open label trial compared the efficacy and safety of once weekly tirzepatide (a dual glucose dependent insulinotropic polypeptide and GLP1 receptor agonist) with semaglutide (a selective GLP1 receptor agonist) in patients with type 2 diabetes inadequately controlled by metformin. The study involved 1879 patients randomized to receive tirzepatide (5 mg, 10 mg, or 15 mg) or semaglutide (1 mg) for 40 weeks. Results showed that tirzepatide was superior to semaglutide in reducing glycated hemoglobin levels (2.01 to 2.30 percentage points vs. 1.86 percentage points) and body weight (7.6 to 11.2 kg vs. 5.7 kg). Gastrointestinal adverse events were common but mostly mild to moderate. Tirzepatide demonstrated noninferiority and superiority to semaglutide, offering a promising treatment option for type 2 diabetes.